计算生物学
核酸酶
生物
基因
DNA
遗传学
否定选择
终止密码子
基因亚型
基因组编辑
碱基对
起始密码子
选择(遗传算法)
抄写(语言学)
病毒学
基因组
人类免疫缺陷病毒(HIV)
dna疫苗
人类基因组
基因产物
药物开发
遗传增强
药品
免疫原性
药物靶点
基因组工程
作者
T. I. Aliev,A.R. Imatdinov,E. Yu. Prudnikova,И.Р. Иматдинов
出处
期刊:PubMed
[National Institutes of Health]
日期:2026-01-01
卷期号:60 (1): 120-131
标识
DOI:10.7868/s3034555326010073
摘要
HIV-1 remains a threat to global health. There is no effective vaccine or drug for a complete cure of HIV infection. Work continues on the development of gene therapy drugs against HIV-1. The use of DNA base editors delivered to the editing site by CRISPR-Cas systems has shown some success in the field of HIV-1 gene therapy. The MmCas12m isoform obtained from Mycolicibacterium mucogenicum can become a promising platform for this task. MmCas12m has a compact size, the ability to bind strongly to the target DNA sequence, and an absence of nuclease activity. Thus, MmCas12m can act not only as a platform for the delivery of DNA base editors, but also as an inhibitor of transcription from HIV-1 proviral DNA. We experimentally selected in vitro the most effective sgRNAs for MmCas12m to target the start codon of the gag HIV-1, the product of which is important in virion assembly. Of the nine sgRNAs we selected, four showed statistically significant effectiveness in targeting the desired region of the HIV-1 genome. To test the effectiveness of each sgRNA, we have developed a system suitable for evaluating the binding of any Cas protein to the target site of HIV-1 genome editing.
科研通智能强力驱动
Strongly Powered by AbleSci AI